EP1071777A2 - Sequences d'acide nucleique humaines provenant du tissu normal de l'uterus - Google Patents
Sequences d'acide nucleique humaines provenant du tissu normal de l'uterusInfo
- Publication number
- EP1071777A2 EP1071777A2 EP99924793A EP99924793A EP1071777A2 EP 1071777 A2 EP1071777 A2 EP 1071777A2 EP 99924793 A EP99924793 A EP 99924793A EP 99924793 A EP99924793 A EP 99924793A EP 1071777 A2 EP1071777 A2 EP 1071777A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- undef
- seq
- nucleic acid
- prostate
- uterus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 157
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 142
- 210000004291 uterus Anatomy 0.000 title abstract description 107
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 31
- 229920001184 polypeptide Polymers 0.000 claims abstract description 29
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 5
- 230000002068 genetic effect Effects 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 132
- 102000004169 proteins and genes Human genes 0.000 claims description 84
- 108020004707 nucleic acids Proteins 0.000 claims description 75
- 102000039446 nucleic acids Human genes 0.000 claims description 75
- 230000000692 anti-sense effect Effects 0.000 claims description 71
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 10
- 208000025421 tumor of uterus Diseases 0.000 claims description 7
- 206010046766 uterine cancer Diseases 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000002823 phage display Methods 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 108020004635 Complementary DNA Proteins 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 230000014107 chromosome localization Effects 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 abstract description 143
- 210000002307 prostate Anatomy 0.000 description 265
- 210000004072 lung Anatomy 0.000 description 208
- 210000000697 sensory organ Anatomy 0.000 description 203
- 210000001672 ovary Anatomy 0.000 description 157
- 210000001550 testis Anatomy 0.000 description 141
- 210000003734 kidney Anatomy 0.000 description 140
- 210000000481 breast Anatomy 0.000 description 137
- 210000004556 brain Anatomy 0.000 description 136
- 230000002440 hepatic effect Effects 0.000 description 136
- 230000002496 gastric effect Effects 0.000 description 126
- 210000001519 tissue Anatomy 0.000 description 109
- 230000003394 haemopoietic effect Effects 0.000 description 91
- 108091060211 Expressed sequence tag Proteins 0.000 description 83
- 108700026244 Open Reading Frames Proteins 0.000 description 83
- 206010028980 Neoplasm Diseases 0.000 description 79
- 150000001413 amino acids Chemical class 0.000 description 78
- 238000011161 development Methods 0.000 description 71
- 230000018109 developmental process Effects 0.000 description 71
- 230000002124 endocrine Effects 0.000 description 70
- 210000003205 muscle Anatomy 0.000 description 69
- 210000004100 adrenal gland Anatomy 0.000 description 68
- 210000004204 blood vessel Anatomy 0.000 description 68
- 210000005036 nerve Anatomy 0.000 description 68
- 210000000056 organ Anatomy 0.000 description 68
- 210000000496 pancreas Anatomy 0.000 description 68
- 210000003899 penis Anatomy 0.000 description 68
- 210000002826 placenta Anatomy 0.000 description 68
- 210000000813 small intestine Anatomy 0.000 description 68
- 230000001605 fetal effect Effects 0.000 description 67
- 210000001625 seminal vesicle Anatomy 0.000 description 63
- 201000010653 vesiculitis Diseases 0.000 description 63
- 206010006256 Breast hyperplasia Diseases 0.000 description 61
- 210000003679 cervix uteri Anatomy 0.000 description 61
- 206010020718 hyperplasia Diseases 0.000 description 61
- 230000000747 cardiac effect Effects 0.000 description 54
- 210000000265 leukocyte Anatomy 0.000 description 33
- 210000002346 musculoskeletal system Anatomy 0.000 description 33
- 210000004696 endometrium Anatomy 0.000 description 28
- 210000000754 myometrium Anatomy 0.000 description 21
- 210000003754 fetus Anatomy 0.000 description 17
- 206010025323 Lymphomas Diseases 0.000 description 14
- 210000001072 colon Anatomy 0.000 description 12
- 108091035707 Consensus sequence Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000000601 blood cell Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 6
- 238000013507 mapping Methods 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101100282116 Candida albicans (strain SC5314 / ATCC MYA-2876) GAP4 gene Proteins 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 101710191958 Amino-acid acetyltransferase Proteins 0.000 description 1
- 102100023167 Argininosuccinate lyase Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 101100447655 Homo sapiens GAS1 gene Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to human nucleic acid sequences from uterine norm tissue which code for gene products or parts thereof, their functional genes, which code at least one biologically active polypeptide and their use.
- the invention further relates to the polypeptides obtainable via the sequences and their use.
- ESTs Extracellular DNA sequences
- cDNAs i.e. reverse transcribed mRNAs
- the EST sequences are determined for normal and degenerate tissues.
- Such databases are partly used by various operators. offered commercially.
- the ESTs in the LifeSeq database used here are typically between 150 and 350 nucleotides long. They represent an unmistakable pattern for a particular gene, although this gene is usually much longer (> 2000 nucleotides).
- ESTs can be identified that are important for tumor development and proliferation.
- the EST sequences found can belong to different regions of an unknown gene due to different constructions of the cDNA libraries, in such a case there would be a completely wrong ratio of the occurrence of these ESTs in the respective tissue. This would only be noticed when the complete gene is known and the ESTs can thus be assigned to the same gene.
- the nucleic acid sequences Seq. ID No 1 to Seq. ID No.62 and Seq. ID 121 to Seq. ID 127 can be found, which play a role as candidate genes in the uterine tumor.
- the nucleic acid sequences Seq are of particular interest. ID Nos. 1-20 and Seq. ID 121 to Seq. ID 127.
- the invention thus relates to nucleic acid sequences which encode a gene product or a part thereof, comprising a) a nucleic acid sequence selected from the group of the nucleic acid sequences Seq ID Nos. 1-20 and Seq. ID 121 to Seq.lD
- nucleic acid sequences mentioned under a) or c) an allelic variation of the nucleic acid sequences mentioned under a) or c) a nucleic acid sequence which is complementary to the nucleic acid sequences mentioned under a) or b).
- the invention further relates to a nucleic acid sequence according to one of the sequences Seq ID Nos 1-20 and Seq. ID 121 to Seq. ID 127 or a complementary or allelic variant thereof and the nucleic acid sequences thereof which have a 90% to 95% homology to a human nucleic acid sequence.
- the invention also relates to the nucleic acid sequences Seq. ID No. 1 to Seq. ID No. 62 and Seq. ID 121 to Seq. ID 127, which are expressed in increased amounts in the uterine norm tissue.
- the invention further relates to nucleic acid sequences comprising a part of the above-mentioned nucleic acid sequences, in such a sufficient size that they can be combined with the sequences Seq. ID Nos 1-20 and Seq. Hybridize ID 121 to Seq. ID 127.
- the nucleic acid sequences according to the invention generally have a length of at least 50 to 4500 bp, preferably a length of at least 150 to 4000 bp, in particular a length of 450 to 3500 bp.
- Expression cassettes can also be used from ID 121 to Seq. ID 127 according to common procedural practice are constructed, wherein on the cassette at least one of the nucleic acid sequences according to the invention together with at least one control or regulatory sequence generally known to the person skilled in the art, such as, for. B. a suitable promoter is combined.
- the sequences according to the invention can be inserted in sense or antisense orientation.
- Expression cassettes or vectors are to be understood: 1. bacterial, such as. B., phagescript, pBs, ⁇ X174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene), pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia), like eukaryont, 2nd eukaryont.
- Suitable control or regulatory sequence means suitable promoters.
- Two preferred vectors are the pKK232-8 and the PCM7 vector.
- the following promoters are specifically meant: la, lacZ, T3, T7, gpt, lambda PR, trc, CMV, HSV thymidine kinase, SV40, LTRs from retrovirus and mouse metallothionein-I.
- the DNA sequences on the expression cassette can encode a fusion protein which comprises a known protein and a biologically active polypeptide fragment.
- the expression cassettes are also the subject of the present invention.
- the nucleic acid fragments according to the invention can be used to produce full-length genes.
- the available genes are also the subject of the present invention.
- the invention also relates to the use of the nucleic acid sequences according to the invention and the gene fragments obtainable from the use.
- the nucleic acid sequences according to the invention can be brought with suitable vectors into host cells in which the genetic information contained on the nucleic acid fragments, which is expressed, is located as a heterogeneous part and is expressed.
- the host cells containing the nucleic acid fragments are also the subject of the present invention.
- Suitable host cells are e.g. B. prokaryotic cell systems such as coli or eukaryotic cell systems such as animal or human cells or yeasts.
- nucleic acid sequences according to the invention can be used in sense or antisense form.
- polypeptides or their fragments are produced by cultivating the host cells in accordance with common cultivation methods and then isolating and purifying the peptides or fragments, likewise by means of conventional methods.
- the invention further relates to nucleic acid sequences which encode at least a partial sequence of a biologically active polypeptide.
- the present invention relates to partial polypeptide sequences, so-called ORF (open reading frame) peptides, according to the sequence protocols Seq. ID Nos 63-117 and Seq. ID Nos. 131-151.
- ORF open reading frame
- the invention further relates to the polypeptide sequences which have at least 80% homology, in particular 90% homology, to the polypeptide partial sequences according to the invention of Seq. ID Nos. 63-117 and Seq. ID Nos. 131-151.
- the invention also relates to antibodies which are directed against a polypeptide or fragment thereof, which of the nucleic acids of the sequences Seq. ID No. 1 to Seq. ID 62 and Seq. ID 121 to Seq.ID 127 can be encoded.
- Antibodies are to be understood in particular as monoclonal antibodies.
- the antibodies of the invention can include can be identified by a phage display method. These antibodies are also the subject of the invention.
- the partial polypeptide sequences according to the invention can be used in a phage display method.
- the polypeptides identified by this method which bind to the partial polypeptide sequences according to the invention are also the subject of the invention.
- the nucleic acid sequences according to the invention can also be used in a phage display method.
- the polypeptides according to the invention of the sequences Seq. ID Nos. 63-117 and Seq. ID Nos. 131-151 can also be used as a tool for finding active substances against the uterine tumor, which is also the subject of the present invention.
- the present invention also relates to the use of the nucleic acid sequences according to the sequences Seq. ID No. 1 to Seq. ID No. 62 and Seq. ID 121 to Seq. ID 127 for the expression of polypeptides which can be used as tools for finding active substances against the uterine tumor.
- the invention also relates to the use of the polypeptide partial sequences Seq found. ID No.
- the invention also relates to medicaments which have at least one polypeptide partial sequence Seq. ID No. 63-117 and Seq. ID Nos. 131-151 included.
- the nucleic acid sequences according to the invention found can also be genomic or mRNA sequences.
- the invention also relates to genomic genes, their exon and intron structure and their splice variants, obtainable from the cDNAs of the sequences Seq. ID No. 1 to Seq. ID No. 62 and Seq. ID 121 to Seq.ID 127, and their use together with suitable regulative elements, such as suitable promoters and / or enhancers.
- Seq. ID No. 1 -62 and Seq. ID 121 to Seq. ID 127 are screened for genomic BAC, PAC and cosmid libraries and specifically human clones are isolated via complementary base pairing (hybridization).
- the BAC, PAC and cosmid clones isolated in this way are hybridized with the aid of fluorescence in situ hybridization to metaphase chromosomes and corresponding chromosome sections are identified on which the corresponding genomic genes lie.
- BAC, PAC and cosmid clones are sequenced in order to elucidate the corresponding genomic genes in their complete structure (promoters, enhancers, silencers, exons and introns).
- BAC, PAC and cosmid clones can be used as independent molecules for gene transfer (see FIG. 5).
- the invention also relates to BAC, PAC and cosmid clones containing functional genes and their chromosomal localization, according to the sequences Seq. ID. No. 1 to Seq. ID No. 62 and Seq. ID 121 to Seq. ID 127, for use as a gene transfer vehicle.
- nucleic acids nucleic acids are to be understood in the full invention: mRNA, partial cDNA, full length cDNA and genomic genes (chromosomes).
- ORF Open Reading Frame, a defined sequence of amino acids that can be derived from the cDNA sequence.
- Module domain of a protein with a defined sequence that represents a structural unit and occurs in different proteins
- N either nucleotide A, T, G or C
- Fig. 1 shows the systematic gene search in the Incyte LifeSeq
- 4a shows the determination of the tissue-specific expression via electronic Northern.
- Figure 5 shows the isolation of BAC and PAC genomic clones.
- a partial DNA sequence S e.g. B. a single EST or a contig of ESTs, using a standard program for homoigies z.
- B. BLAST (Altschul, SF, Gish W., Miller, W., Myers, EW and Lipman, DJ (1990) J. Mol. Bio, 215, 403-410), BLAST2 (Altschul, SF, Madden, T. L, Schaffer, A. A "Zhang, J., Zhang, Z., Miller, W. and Lipman, DJ (1997) Nucleic Acids
- tissue-ordered (private or public) EST libraries certainly.
- FASTA Pearson, WR and Lipman, DJ (1988) Proc. Natl. Acad. Sci. USA 85 2444-2448
- the (relative or absolute) tissue-specific occurrence frequencies of this partial sequence S determined in this way are referred to as electronic Northern blot.
- Musculoskeletal system 0.0103 0.0120 0.85671.1673
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19817946A DE19817946A1 (de) | 1998-04-17 | 1998-04-17 | Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe |
DE19817946 | 1998-04-17 | ||
PCT/DE1999/001175 WO1999054353A2 (fr) | 1998-04-17 | 1999-04-15 | Sequences d'acide nucleique humaines provenant du tissu normal de l'uterus |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1071777A2 true EP1071777A2 (fr) | 2001-01-31 |
Family
ID=7865424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99924793A Withdrawn EP1071777A2 (fr) | 1998-04-17 | 1999-04-15 | Sequences d'acide nucleique humaines provenant du tissu normal de l'uterus |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1071777A2 (fr) |
JP (1) | JP2002512017A (fr) |
DE (1) | DE19817946A1 (fr) |
WO (1) | WO1999054353A2 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000053754A1 (fr) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Compositions et methodes pour le traitement de tumeurs |
US6372473B1 (en) | 1997-05-28 | 2002-04-16 | Human Genome Sciences, Inc. | Tissue plasminogen activator-like protease |
NZ525914A (en) * | 1998-03-10 | 2004-03-26 | Genentech Inc | Novel polypeptides and nucleic acids encoding the same |
AU2002301608C1 (en) * | 1998-03-10 | 2005-08-11 | Genentech, Inc. | Novel PRO351 Polypeptides and Nucleic Acids Encoding Same |
US7723488B2 (en) | 1998-03-27 | 2010-05-25 | Genentech, Inc. | Monoclonal antibodies to secreted and transmembrane polypeptides |
ES2317967T5 (es) * | 1998-04-22 | 2013-03-19 | Genentech, Inc. | Proteína GAS-6 (GROWTH ARREST-SPECIFIC GENE 6) humana y ácidos nucleicos que la codifican |
DE60039708D1 (de) * | 1999-10-18 | 2008-09-11 | Lexicon Pharmaceuticals Inc | Menschliches chordin und polynukleotiden die dafür kodieren |
EP1230359A1 (fr) * | 1999-11-10 | 2002-08-14 | Compugen Ltd. | Homologues de type chordine |
WO2001064885A1 (fr) * | 2000-03-02 | 2001-09-07 | Amgen, Inc. | Molecules de type chordine 2 et utilisations de celles-ci |
CA2410895A1 (fr) | 2000-05-31 | 2001-12-06 | Genzyme Corporation | Composes therapeutiques pour cancer de l'ovaire |
AU2001294943A1 (en) * | 2000-10-02 | 2002-04-15 | Bayer Corporation | Nucleic acid sequences differentially expressed in cancer tissue |
WO2003050307A1 (fr) * | 2001-12-05 | 2003-06-19 | Genzyme Corporation | Composes destines a la therapie et au diagnostic et procedes d'utilisation associes |
GB0216727D0 (en) * | 2002-07-17 | 2002-08-28 | Univ Cambridge Tech | Genes |
NZ550110A (en) | 2004-04-14 | 2009-09-25 | Genentech Inc | Compositions and methods comprising an EGFL7 antagonist for modulating vascular development |
CA2760246A1 (fr) | 2009-05-08 | 2010-11-11 | Weilan Ye | Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024655A1 (fr) * | 1992-05-27 | 1993-12-09 | Amersham International Plc | Analyse d'arn |
DE19820190A1 (de) * | 1998-04-28 | 1999-11-04 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Pankreas-Tumor |
-
1998
- 1998-04-17 DE DE19817946A patent/DE19817946A1/de not_active Withdrawn
-
1999
- 1999-04-15 WO PCT/DE1999/001175 patent/WO1999054353A2/fr not_active Application Discontinuation
- 1999-04-15 EP EP99924793A patent/EP1071777A2/fr not_active Withdrawn
- 1999-04-15 JP JP2000544691A patent/JP2002512017A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9954353A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999054353A2 (fr) | 1999-10-28 |
JP2002512017A (ja) | 2002-04-23 |
DE19817946A1 (de) | 1999-10-21 |
WO1999054353A3 (fr) | 2000-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1071777A2 (fr) | Sequences d'acide nucleique humaines provenant du tissu normal de l'uterus | |
DE69434926T2 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
EP1076700A2 (fr) | Sequences nucleotidiques humaines obtenues a partir d'un tissu tumoral du pancreas | |
WO1999054461A2 (fr) | Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre | |
EP1291422A2 (fr) | Sequences d'acide nucleique humaine provenant de tissu de tumeur ovarienne | |
DE69530944T2 (de) | Keratinozyten-wachstumsfaktor 2 | |
EP1234879B1 (fr) | Séquence d'acide nucléique humaine issue de tissus tumoraux prostatiques | |
EP1073742A2 (fr) | Sequences d'acide nucleique provenant de tissus tumoraux de la vessie | |
US20020065394A1 (en) | Secreted proteins and polynucleotides encoding them | |
WO1999054460A2 (fr) | Sequences d'acide nucleique provenant du tissu normal de la vessie | |
Shimizu et al. | Molecular cloning of a novel NF2/ERM/4.1 superfamily gene, ehm2, that is expressed in high-metastatic K1735 murine melanoma cells | |
WO1999047655A2 (fr) | Sequences d'acides nucleiques humains provenant de tissus mammaires sains | |
CA2379784A1 (fr) | Proteines du cycle et de proliferation cellulaires | |
EP1080188A2 (fr) | Sequences d'acide nucleique provenant d'un fibrome uterin | |
DE60117788T2 (de) | Menschliche wingless-ähnliche gene | |
WO1999054446A2 (fr) | Sequences d'acides nucleiques humains provenant de tissus sains du pancreas | |
US20040152873A1 (en) | Novel gene bn01 mapping to chromosone 16q24.3 | |
US20030028907A1 (en) | Novel human kielin-like proteins and polynucleotides encoding the same | |
US6503502B1 (en) | Nucleotide sequences, proteins, drugs and diagnostic agents of use in treating cancer | |
US20040247555A1 (en) | Methods of and compositions for modulating hair growth via P-cadherin modulators | |
CA2452260C (fr) | Nouveaux variants et exons du transporteur glyt1 | |
US20040002471A1 (en) | Human nucleic acid sequences which are overexpressed in normal pancreas tissue | |
US6777232B1 (en) | Human membrane proteins and polynucleotides encoding the same | |
US20030022329A1 (en) | Novel nucleic acids and polypeptides | |
US20030017545A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001009 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: METAGEN PHARMACEUTICALS GMBH |
|
17Q | First examination report despatched |
Effective date: 20040213 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PILARSKY, CHRISTIAN, DR. Owner name: SPECHT, THOMAS, DR. Owner name: ROSENTHAL, ANDRE, PROF. Owner name: HINZMANN, BERND, DR. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040624 |